Literature DB >> 29413510

Prevalence and impact of respiratory symptoms in a population of patients with COPD in Latin America: The LASSYC observational study.

Marc Miravitlles1, Ana Menezes2, Maria Victorina López Varela3, Alejandro Casas4, Luis Ugalde5, Alejandra Ramirez-Venegas6, Laura Mendoza7, Ana López8, Fernando C Wehrmeister2, Filip Surmont9, Maria Montes de Oca10.   

Abstract

BACKGROUND: To analyse the relationship between symptoms at different times during the 24-hour day and outcomes in COPD.
METHODS: Observational cross-sectional study in a patients from 7 Latin American countries. The frequency of symptoms in the morning, at night and during the day was explored by means of standardised and validated questionnaires, and the relationship between symptoms and exacerbations and quality of life were investigated.
RESULTS: 734 patients (59.6% male, mean age 69.5 years, mean FEV1 50% predicted normal) were recruited. The most frequent symptoms during the day were dyspnea (75% of patients, of which 94% mild-moderate) and cough (72.2%, of which 93.4% mild-moderate). Highly symptomatic patients had a greater impairment in FEV1, more exacerbations and worse scores in COPD assessment test (CAT) and Body Mass Index, Obstruction, Dyspnoea and Exacerbations (BODEx) index (all p < 0.001). Morning symptoms were more frequent than night-time symptoms, particularly cough and dyspnoea (morning: 50.1% and 45.7%; night-time: 33.2% and 24.4%, respectively), and mostly rated as mild or moderate. Patients with morning or night-time symptoms presented with worse severity of daytime symptoms. There was a strong correlation between intensity of daytime with morning or night-time symptoms, as well as with CAT score (r = 0.715; p < 0.001), but a weak correlation with FEV1 (r = -0.205; p < 0.001).
CONCLUSION: Morning symptoms were more frequent than night-time symptoms, and having either morning and/or night-time symptoms was associated with worse severity of daytime symptoms. Increased symptoms were strongly associated with worse quality of life and more frequent exacerbations, but weakly associated with airflow limitation. CLINICAL TRIAL REGISTRATION: NCT02789540.
Copyright © 2017 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Exacerbations; Latin America; Quality of life; Symptoms

Mesh:

Year:  2017        PMID: 29413510     DOI: 10.1016/j.rmed.2017.11.018

Source DB:  PubMed          Journal:  Respir Med        ISSN: 0954-6111            Impact factor:   3.415


  7 in total

1.  Respiratory medication used in COPD patients from seven Latin American countries: the LASSYC study.

Authors:  Alejandro Casas; Maria Montes de Oca; Ana Mb Menezes; Fernando C Wehrmeister; Maria Victorina Lopez Varela; Laura Mendoza; Larissa Ramírez; Marc Miravitlles
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2018-05-11

2.  Evaluating the impact of morning symptoms in COPD using the Capacity of Daily Living during the Morning (CDLM) questionnaire.

Authors:  Alexa Núñez; Cristina Esquinas; Miriam Barrecheguren; Myriam Calle; Ricard Casamor; Marc Miravitlles
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2018-11-26

3.  Heterogeneity in the respiratory symptoms of patients with mild-to-moderate COPD.

Authors:  Kate M Johnson; Abdollah Safari; Wan C Tan; Jean Bourbeau; J Mark FitzGerald; Mohsen Sadatsafavi; On Behalf Of The Canadian Cohort Of Obstructive Lung Disease CanCOLD Study
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2018-12-13

4.  Symptom variability over the course of the day in patients with stable COPD in Brazil: a real-world observational study.

Authors:  Alberto Cukier; Irma de Godoy; Claudia Henrique da Costa; Adalberto Sperb Rubin; Marcelo Gervilla Gregorio; Aldo Agra de Albuquerque Neto; Marina Andrade Lima; Monica Corso Pereira; Suzana Erico Tanni; Rodrigo Abensur Athanazio; Elizabeth Jauhar Cardoso Bessa; Fernando Cesar Wehrmeister; Cristina Bassi Lourenco; Ana Maria Baptista Menezes
Journal:  J Bras Pneumol       Date:  2019-12-20       Impact factor: 2.624

Review 5.  High-Density Lipoproteins: A Role in Inflammation in COPD.

Authors:  Stanislav Kotlyarov
Journal:  Int J Mol Sci       Date:  2022-07-23       Impact factor: 6.208

Review 6.  What have we learned from observational studies and clinical trials of mild to moderate COPD?

Authors:  Miriam Barrecheguren; Cruz González; Marc Miravitlles
Journal:  Respir Res       Date:  2018-09-17

7.  A shadow in the GOLD ABCD classification system: measurement of perception of symptoms in COPD.

Authors:  Ernesto Crisafulli; Giulia Sartori
Journal:  J Bras Pneumol       Date:  2021-12-01       Impact factor: 2.800

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.